Azasetron is an antiemetic which acts as a 5-HT3 antagonist, 5-HT
3 receptor receptor antagonist, antagonist, pK
i = 9.27 It is used in the management of nausea and vomiting induced by cancer chemotherapy (such as cisplatin chemotherapy). Azasetron hydrochloride is given in a usual dose of 10 mg once daily by mouth or intravenously. It is approved for marketing in Japan, and marketed exclusively b
Torii Pharmaceutical Co., Ltd.under the trade names "Serotone I.V. Injection 10 mg" and "Serotone Tablets 10 mg". Pharmacokinetics data from S. Tsukagoshi.
Arazasetron besylate (SENS-401) is an investigational drug formulation containing exclusively the ''R''-enantiomer of azasetron. The compound has been studied to prevent hearing loss related to sudden sensorineural hearing loss (SSNHL),
acoustic trauma,
and cisplatin-induced ototoxicity.
References
5-HT3 antagonists
Morpholinones
Quinuclidines
Lactams
Chlorobenzene derivatives
Salicylamide ethers
Cyclic ethers
{{gastrointestinal-drug-stub